Outcomes of Black (B) versus White (W) patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation therapy (ADT) with or without orteronel (Ort): Analysis of pt-level data from SWOG-1216 phase 3 trial.

Authors

Nicolas Sayegh

Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT

Nicolas Sayegh , Umang Swami , Yeonjung Jo , Georges Gebrael , Benjamin Haaland , Shilpa Gupta , Melissa Plets , Maha H. A. Hussain , David I. Quinn , Primo N Lara Jr., Ian M Thompson Jr., Neeraj Agarwal

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Prostate-specific antigen value at 3 & 7 months (PSA-3mo, PSA-7mo) and overall survival (OS) in metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation (ADT) with or without orteronel (SWOG S1216).

First Author: Mamta Parikh

insert_chart_outlined

Poster

2020 ASCO Virtual Scientific Program

bookmark_border

Bone metabolism biomarkers (BMB) and progression-free survival (PFS) in men with metastatic hormone-sensitive prostate cancer (HSPC): SWOG S1216, a phase III trial of androgen deprivation therapy (ADT) with or without orteronel.

First Author: Primo Lara Jr.

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Baseline circulating tumor cell (CTC) count as a prognostic marker of overall survival (OS) in metastatic hormone sensitive prostate cancer (mHSPC): Results from SWOG S1216, a phase III randomized trial of androgen deprivation plus orteronel (cyp17 inhibitor) or bicalutamide.

First Author: Amir Goldkorn

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

Bone biomarkers and overall survival (OS) in men with advanced hormone-sensitive prostate cancer (HSPC): Results from SWOG S1216, a phase III trial of ADT +/- orteronel.

First Author: Primo "Lucky" N. Lara Jr.